Hormonal contraception is not associated with recurrent flares in ulcerative colitis: a longitudinal time-dependent analysis: GI Signals

IBD retrospective · n=225 · Aug 18, 2026 · Inflamm Bowel Dis · IF 4.5

Hormonal contraception is not associated with recurrent flares in ulcerative colitis: a longitudinal time-dependent analysis.

New evidenceulcerative colitisbiomarker

Clinical takeawayCounsel women with UC seeking contraception that available evidence does not support an increased UC flare risk with HCT. Although C-reactive protein does increase modestly during HCT exposure, this does not manifest as increased flares or cumulative inflammatory burden. Offer HCT as a contraceptive option while noting the modest sample size of exposed women, which limits power to detect rare or smaller effects.

What it foundHormonal contraception was not associated with increased recurrent ulcerative colitis flares (aHR 0.93, 95% CI 0.62-1.40) over 5.3 years median follow-up with 374 flares observed; cumulative inflammatory burden remained comparable. C-reactive protein was significantly higher during HCT-exposed months (β=0.254, P=.0038), but platelet count, ESR, albumin, alpha-1-acid glycoprotein, and fecal calprotectin were not. No safety signals were identified. However, only 58 of 225 women were exposed to HCT, and this modest sample cannot exclude smaller effects or rare outcomes.

ContextAddresses a common clinical uncertainty: many gastroenterologists may counsel against hormonal contraception due to inflammation concerns, but this data clarifies that HCT is safe in UC. Refines understanding of HCT safety without identifying new protective or harmful effects.

Emergingsuggested applicable standard· ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes)

Decision at stakewhether women with ulcerative colitis should avoid hormonal contraception based on flare risk

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. … Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. Treat mild-moderate disease with 5-ASA by route and extent (suppository for proctitis, enema for left-sided, oral plus rectal for extensive); if 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by EFFICACY TIER, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab; intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab; lower: adalimumab. PREVIOUSLY TNF-EXPOSED, higher efficacy: tofacitinib, upadacitinib, ustekinumab; lower: adalimumab, vedolizumab, ozanimod, etrasimod - S1P modulators are weakest in exactly this group. Do not cycle within the anti-TNF class after primary non-response; switch mechanism. Apply treat-to-target (STRIDE-II) to endoscopic improvement (MES 0-1). Screen for acute severe UC by Truelove-Witts and admit for IV steroids. Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.

ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes) ↗

Gros B … Iglesias-Flores EM · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink